65,437 trials
Type 2 Diabetes Mellitus
Primary: HbA1c at 4 Months — 8.2; 8.4; 8.1 percentage glycated hemoglobin
Multiple Sclerosis
Primary: Serum Level of TNF-α — 37.16; 28.79 Pg/ml
Cystic Fibrosis
Primary: Adverse Event Profile of 560 mg Once Daily Dose of Arikayce™ Administered for Six Cycles Over Eighteen Months. — 48; 15; 28; 15 participants
Anesthesia
Primary: R-methadone Plasma AUC 0-96hr/Dose — 228; 189; 205; 0 (ng * hr-1 * ml-1 * mg-1 — p=<0.05
Hip Labral Tears
Primary: Visual Analog Score for Pain (VAS) in the Immediate Post Operative Period — 2.11; 2.33; 4.41; 5.02 score on a scale
Chikungunya Virus Infection
Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Any Injection — 136; 161; 58; 37 Participants
Neonatal Abstinence Syndrome · Aromatherapy
Primary: Length of Hospitalization — 17.8; 11.4 days — p=0.03
Recurrent Respiratory Papillomatosis · Juvenile Laryngeal Papilloma · Laryngeal Papilloma, Recurrent
Primary: Number of Patients With Laryngotracheal Recurrent Respiratory Papillomatosis (RPP) Who Achieve a Complete Response With Avelumab as Measured by Derkay Score Calculated…
Biliary Colic
Primary: Pain Score 120 Minutes After Study Medication Administration — 3.0; 0.3 score on a scale
Rheumatoid Arthritis
Primary: Measuring the Safety and Efficacy of a New DMARD, Leflunomide Alone or in Combination With Traditional DMARD's. Participants Reaching ACR 20 Response. at 48 Weeks — 8…
Functional Constipation in Children Ages 6-17 Years
Primary: Change From Baseline (CFB) in 4-week Overall Spontaneous Bowel Movement (SBM) Frequency Rate During the Treatment Period — 2.000; 1.412; 1.814; 2.364 SBMs/week — p=0.3097
Ebola Virus Infection
Primary: Mortality — 13; 8 Participants
Heart Failure · Obstructive Sleep Apnea · Heart Failure, Congestive
Primary: Left Ventricular Ejection Fraction (LVEF) — 25.3; 27.0; 27.3; 28.8 percent ejection fraction
Healthy Volunteers · Pharmacokinetics
Primary: Peak Plasma Concentration (Cmax) — 222; 229; 1567; 1684 ng/mL
Plaque Psoriasis
Primary: Maintenance of PASI 90 Response at Week 52 in Participants With a PASI 90 Response at Week 24 — 552; 496 Participants — p=0.1499